Compass Pathways Plc Q4 FY2024 earnings call

• Thanked investors for financing last month, which positions the company to complete COMP360 program in TRD and progress PTSD development. • Eagerly await top line results from 005 trial's 6-week primary endpoint in Q2, with over 90% of patients recruited. • 006 trial enrollment going well, with 005 sites converting to 006 sites upon 005 enrollment completion. • Expect top line 6-week primary endpoint data from 005 towards end of next quarter and 26-week data once 006 participants complete Part A. • 006 trial 26-week results expected in second half of 2026. • Continuing preparations for launch of potentially paradigm-changing treatment in TRD and PTSD. • Strategic collaborations with health care delivery organizations provide insights for launch and scaling.

No specific product segment financial performance or revenue contribution details provided in the transcript.

• Expect net cash used in operations for 2025 to be within $120 million to $145 million. • Anticipate top line 6-week primary endpoint data from 005 towards end of next quarter. • Expect 26-week results from 006 trial in second half of 2026.

• No specific risks detailed in the transcript beyond general mention of risks in forward-looking statements as described in SEC filings.

Q: Gavin Clark-Gartner asked about the 6-week MADRS Delta and bar for 005 top line, and framing on PTSD advisory committee meeting.

A: Kabir Nath and Guy Goodwin responded discussing use of Phase 2b data as benchmark and interest in patient population view for PTSD.

Q: Paul Matteis asked about top line disclosure for 005, safety commentary, and enrollment.

A: Kabir Nath responded on efficacy disclosure, safety statement from DSMB on suicidal ideation, and recruitment progress for 005 and 006.

Q: Ritu Baral asked about additional analysis with top line, patient disposition, and powering of study.

A: Kabir Nath and Guy Goodwin responded on no secondary analysis with 6-week data, patient disposition impressions, and willingness to share powering details once data is available.

Q: Charles Duncan asked about suicidal ideation commentary in 005 and DSMB review.

A: Guy Goodwin and Teri Loxam responded on expected suicidal ideation, DSMB's clinical judgment on safety, and patient population risk.

Q: Leonid Timashev asked about durability measurement, FDA view, and future medication use.

A: Guy Goodwin responded on durability as early response maintenance, capturing time to new treatment, and clinical perspective on patients using maintenance antidepressants.

Q: Patrick Trucchio asked about clinically meaningful MADRS improvement at 6-weeks and psychological support model.

A: Kabir Nath and Guy Goodwin responded on MADRS effect difference, and psychological support model for FDA understanding and clinical training.

Q: François Brisebois asked about chief patient officer role and 005/006 timing.

A: Steve Levine and Kabir Nath responded on chief patient officer's role in incorporating patient perspectives, and timing uncertainty for 005 and 006 data readouts.

Q: Sumant Kulkarni asked about MADRS bar, competition with other psychedelic compounds, and FDA interactions.

A: Kabir Nath, Guy Goodwin, Lori Englebert, and Steve Levine responded on TRD bar, reimbursement codes and economics, and FDA interaction neutrality.

Q: Michael Rabinowitz asked about pipeline plans and Spravato adoption impact.

A: Kabir Nath and Lori Englebert responded on anorexia study data in 2025, focus on TRD and PTSD, and Spravato's role in preparing market for COMP360.

Q: Vikram Purohit asked about PTSD prioritization and path to filing.

A: Kabir Nath and Guy Goodwin responded on PTSD unmet need and regulatory development considerations.

Q: François Brisebois asked about DSMB interaction recentness and frequency.

A: Kabir Nath responded on recent DSMB interaction this month and quarterly cadence.